

OTCMarkets

Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines

PATIENT ACCESS SOLUTIONS INC.
A NEVADA Corporation
150 VETERANS HIGHWAY
COMMACK, NY 11725

800-570-8404
WWW.PASHEALTH.COM
SIC 8090

QUARTERLY REPORT
For the Period Ending:
JANUARY 31, 2021
(the "Reporting Period")

As of January 31, 2021, Current Reporting Period, the number of shares outstanding of our Common Stock was: 1,298,185,907
As of October 31, 2020 Prior Reporting Period, the number of shares outstanding of our Common Stock was 1,157,825,270
As of October 31, 2020, Completed Fiscal Year End the number of shares outstanding of our Common Stock was: 1,157,825,270

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933 and Rule 12b-2 of the Exchange Act of 1934):

Yes: ☐ No: ☒ XX (Double-click and select "Default Value" to check)

Indicate by check mark whether the company's shell status has changed since the previous reporting period: Yes: ☐ No: ☒ XX

Indicate by check mark whether a Change in Control¹ of the company has occurred over this reporting period: Yes: ☐ No: ☒ XX

I "Change in Control" shall mean any events resulting in:

- (i) Any person (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the "beneficial owner" (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

1) Name of the issuer and its predecessors (if any)

In answering this item, please also provide any names used by predecessor entities and the dates of the name changes.

Current Issuer- Patient Access Solutions Inc., previously named Blue Mountain Resources, Inc.- name changed on June 2, 2008. On March 31, 2008, Patient Access Solutions Inc., a New York corporation, merged into Blue Mountain Resources,

Date and state (or jurisdiction) of incorporation (also describe any changes to incorporation since inception, if applicable) The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

2006 State of Nevada- Active in Good Standing

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

none

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

A stock dividend was issued in 2020 as a Preferred Stock C issuance at a 1 share preferred for 5000 shares of common stock

The address(es) of the issuer's principal executive office:

104-60 Queens Blvd, Forest Hills, NY 11375

The address(es) of the issuer's principal place of business:

Check box if principal executive office and principal place of business are the same address: **XX**

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

Yes: ☐ No: **XX**

If this issuer or any of its predecessors have been the subject of such proceedings, please provide additional details in the space below:

n/a

2) Security Information

Trading symbol:	<u>PASO</u>	
Exact title and class of securities outstanding:	<u>Common Stock</u>	
CUSIP:	<u>70324A208</u>	
Par or stated value:	<u>.001</u>	
Total shares authorized:	<u>2,500,000,000</u>	as of date: <u>January 31, 2021</u>
Total shares outstanding:	<u>1,298,185,907</u>	as of date: <u>January 31, 2021</u>
Number of shares in the Public Float ¹ :	<u>712,418,451</u>	as of date: <u>January 31, 2021</u>
Total number of shareholders of record:	<u>539</u>	as of date: <u>January 31, 2021</u>

All additional class(es) of publicly traded securities (if any):

Trading symbol:	<u>PASO</u>	
Exact title and class of securities outstanding:	<u>Preferred A</u>	
CUSIP:	<u>70324A208</u>	
Par or stated value:	<u>.001</u>	
Total shares authorized:	<u>10,000,000</u>	as of date: <u>January 31, 2021</u>
Total shares outstanding:	<u>10,000,000</u>	as of date: <u>January 31, 2021</u>

¹ "Public Float" shall mean the total number of unrestricted shares not held directly or indirectly by an officer, director, any person who is the beneficial owner of more than 10 percent of the total shares outstanding (a "control person"), or any affiliates thereof, or any immediate family members of officers, directors and control persons.

Trading symbol: PASO
Exact title and class of securities outstanding: Preferred C
CUSIP: 7SP993104
Par or stated value: .001
Total shares authorized: 3,000,000 as of date: January 31, 2021
Total shares outstanding: 244,312 as of date: January 31, 2021

Transfer Agent

Name: Empire Stock Transfer
Phone: 702-818-5898
Email: info@empirestock.com

Is the Transfer Agent registered under the Exchange Act?² Yes: XX ☐ No: ☐

Describe any trading List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

Corporate action of Patient Access Solutions. Both these actions involve the new Series C Convertible Preferred Stock. The first is a dividend to all shareholders of record on September 18, 2020 at the close of the market. For every 5,000 shares of common stock then owned, each shareholder received one (1) Series C Convertible Preferred share. This will be processed as follows:

DTC will receive a block of Series C shares from the Transfer Agent and then these Series C shares will be distributed to each shareholder's brokerage firm automatically.

The second item the Company has authorized is a tender offer for all common shareholders of record on the same date. The way this is done is by the shareholder exchanging their common shares for the new Series C Convertible Preferred stock. That conversion rate will be one (1) share of the new Preferred for every 250 shares of common owned.

3) Issuance History

The goal of this section is to provide disclosure with respect to each event that resulted in any direct changes to the total shares outstanding of any class of the issuer's securities in the past two completed fiscal years and any subsequent interim period.

Disclosure under this item shall include, in chronological order, all offerings and issuances of securities, including debt convertible into equity securities, whether private or public, and all shares or any other securities or options to acquire such securities issued for services. Using the tabular format below, please describe these events.

² To be included in the Pink Current Information tier, the transfer agent must be registered under the Exchange Act.

A. Changes to the Number of Outstanding Shares SEE ATTACHED

Check this box to indicate there were no changes to the number of outstanding shares within the past two completed fiscal years and any subsequent periods: ☐ D

Number of Shares outstanding as of [Date of] 10/31/20	Opening Balance: Common: 1,157,825,270 Preferred A: 10,000,000 Preferred C: 244,312 ¹ October 31, 2020		-Right-click the rows below and select insert to add rows as needed;						
Beginning of Second Most Recent Completed Year 10/31/19	Opening Balance: Common: 422,853,751 Preferred: 10,000,000 October 31, 2019								
Date of Transaction	Transaction type (e.g. new Issuance, cancellation, shares returned to	Number of Shares Issued (or cancelled)	Class of Securities	Value of shares Issued (\$/per share) at Issuance	Were the shares Issued at a discount to market price at the time of Issuance? (Yes/No)	individual Entity Shares were Issued to (entitles must have individual with voting / Investment control disclosed).	Reason for share Issuance (e.g. for cash or debt conversion) OR Nature of Services Provided (I f applicable)	Restricted or Unrestricted as of this filing?	Exemption or Registration Type?
	treasury)								
-	See attached-	-see attached							
Shares Outstanding On Date of this 1/31/2021	Ending Balance: Common: 1,298,185,907 Preferred A: 10,000,000 Preferred C: 244,312 January 31,2021		1 Each share of Preferred C , after a 12 month holding period, may be converted to 250 shares of common stock.						

Example: A company with a fiscal year end of December 31st in addressing this item for its quarter ended September 30, 2018, would include any events that resulted in changes to any class of its outstanding shares from the period beginning on January 1, 2016 through September 30, 2018 pursuant to the tabular format above.

Use the space below to provide any additional details, including footnotes to the table above:

Date of Transaction	Type	CERTIFICATE#	HOLDER	NUMBER of SHARES
PASO Stock Issuance				
11/6/2018	COMMON	ROSEMARIE ROTUNDO		2,000,000
1/2/2019	COMMON	ZVI JACOBOWITZ		1,500,000
1/8/2019	COMMON	EMMANUEL KRAMER		4,102 ,23 1
2/15/2019	COMMON	VICTOR SCAVO		15 ,000 ,000
3/13/2019	COMMON	RAFIA HAMID		500,000
3/13/2019	COMMON	STEVE MEDINA		1,000,000
3/13/2019	COMMON	RAYMOND CHIN		8,000,000
05 /14/2019	COMMON	SALVO DAGUANNO		5,000,000
06/23/2019	COMMON	MICHAEL KRUEGER		500,000
06/23/2019	COMMON	LAUREN KRUEGER		500,000
08/02/2019	COMMON	JEFFERY KRUEGER		13,250,000
08/05/2019	COMMON	EMMANUEL KRAMER		5,732,825
09/01/2019	COMMON	JAG CAPITAL (Joseph Gonzalez)		23,000,000
09/01/2019	COMMON	ROBERT LINZALONE		10,000,000
09/10/2019	COMMON	HESTIA INVESTMENT (Edward Lee)		2,000,000
09/19/2019	COMMON	JEFFERY KRUEGER		962,000
09/20/2019	COMMON	DREAMTECH INC. (Anthony Pizzolo)		10,000,000
09/20/2019	COMMON	DREAMTECH INC. (Anthony Pizzolo)		3,000,000
09/20/2019	COMMON	DOVECOTE CONSULTING SERVICES (Anthony Pizzolo)		3,000,000
12/10/2019	COMMON	ROBERT LINZALONE		13,000,000
12/10/2019	COMMON	ROBERT LINZALONE		23,000,000
12/10/2019	COMMON	BRUCE WEITZBERG		13,000,000
01/09/2020	COMMON	JEFFERY KRUEGER		7,319,302
01/09/2020	COMMON	RANDALL BRODSKY		576,191
01/15/2020	COMMON	HESTIA INVESTMENTS (Edward Lee)		2,100,000
01/27/2020	COMMON	JOSEPH GONZALEZ		20,000,000
01/27/2020	COMMON	JAG CAPITAL (JOSEPH Gonzalez)		23,000,000
01/30/2020	COMMON	136 MICHAEL KRUEGER		5,000,000
01/30/2020	COMMON	137 LAUREN KRUEGER		5,000,000
01/30/2020	COMMON	135 JEFFERY KRUEGER		4,687,412
02/10/2020	COMMON	647 Cortney McCown		2,000,000
02/10/2020	COMMON	648 Joseph Bartnick		500,000
02/10/2020	COMMON	535 RONALD GONZALEZ		4,000,000
02/10/2020	COMMON	649 Eric Gonzalez		5,000,000
02/10/2020	COMMON	650 Patricia Gonzalez		5,000,000
02/10/2020	COMMON	631 ELLIOTT POLATOFF		4,500,000
02/10/2020	COMMON	651 Matthew Ketterman		1,000,000
02/10/2020	COMMON	497 AMJ GLOBAL ENTERTAINMENT LLC(Art Malone)		5,726,954
02/10/2020	COMMON	652 Jeffrey Gullo		1,500,000
02/10/2020	COMMON	648 Joseph Bartnick		500,000
02/10/2020	COMMON	653 Affinity Advisors, LLC (Dan Luther)		5,000,000
02/12/2020	COMMON	654 Lee H. Puglisi		4,000,000
03/13/2020	COMMON	Blackthorne Development (Mike Collins)		10,000,000
03/13/2020	COMMON	682 Brian Cesca		250,000
03/13/2020	COMMON	683 Cortney McCown		5,000,000
03/13/2020	COMMON	684 Jarvis Shockey		3,000,000
03/13/2020	COMMON	685 Wong Hang NGA		2,000,000
03/16/2020	COMMON	518 TOPPER PARTNERS I, LLC (Vic Topper)		9,806,969
03/17/2020	COMMON	655 Ashley Williams		4,000,000
03/17/2020	COMMON	134 JOSEPH GONZALEZ		2,000,000
03/18/2020	COMMON	656 Jordan Scott Walker		270,000
03/18/2020	COMMON	657 Leslie Iris Kubrick		125,000
03/18/2020	COMMON	658 Andrew Howard Kubrick		125,000
03/18/2020	COMMON	659 Samantha Danielle Kubrick		10,000

03/18/2020	COMMON	660 Alexis Nicole Kubrick	10,000
03/18/2020	COMMON	661 Joseph Daniel Secreti	10,000
03/18/2020	COMMON	662 Sheldon Walker	5,000,000
03/24/2020	COMMON	89 CAROLINE IGLIO	2,000,000
04/01/2020	COMMON	497 JEBAC LLC (Jerry Krystoff)	15,000,000
04/01/2020	COMMON	497 MARK PRESLEY	2,500,000
04/01/2020	COMMON	664 SCOTT IACONO	150,000
04/01/2020	COMMON	665 CARRAN SCHNEIDER	5,000,000
04/07/2020	COMMON	654 LEE PUGLISI	4,000,000
04/07/2020	COMMON	615 FRANK PACKES	2,250,000
05/20/20	COMMON	DREAMTECH INC. (Anthony Pizzolo)	40,000,000
05/20/20	COMMON	46 ROBERT LINZALONE	21,600,000
05/21/20	COMMON	654 Lee H. Puglisi	10,000,000
05/27/20	COMMON	135 JEFFERY J. KRUEGER	10,700,000
06/05/20	COMMON	497 AMJ GLOBAL, LLC (Art Malone)	5,650,322
06/16/20	COMMON	497 AMJ GLOBAL, LLC(Art Malone)	3,750,322
09/02/20	COMMON	558 ROBERT MEIBORG LIVING TRUST	17,379,000
09/02/20	COMMON	566 ALM DEVELOPMENT 401K (Bob Meiborg)	30,278,774
09/02/20	COMMON	DREAMTECH INC. (Anthony Pizzolo)	16,000,000
09/02/20	COMMON	497 AMJ Global LLC (Art Malone)	10,000,000
09/04/20	COMMON	677 Saul E. Feder	4,000,000
09/04/20	COMMON	663 Carran Schneider	15,000,000
09/04/20	COMMON	678 Amanda Damarin	15,000,000
09/04/20	COMMON	662 Sheldon Walker	4,500,000
09/04/20	COMMON	256 SEAN MCNAMARA	2,000,000
09/09/20	COMMON	134 JOSEPH GONZALEZ	6,000,000
09/11/20	COMMON	588 MICHAEL J KRUEGER	10,700,000
09/11/20	COMMON	587 LAUREN KRUEGER	10,700,000
09/11/20	COMMON	478 ALEXANDRA ARENA &	62,500
09/11/20	COMMON	484 LEANNE ARENA &	125,000
		LAWRENCE ARENA JT TEN	
09/11/20	COMMON	482 LEANNA ARENA &	62,500
		DOMENIC ARENA JT TEN	
09/11/20	COMMON	483 LEANNE ARENA &	62,500
		DANILYN ARENA JT TEN	
09/11/20	COMMON	480 ALFONSO ARENA &	125,000
		ANTONETTE ARENA JT TEN	
09/11/20	COMMON	476 RICHARD MERZ &	125,000
		INGE MERZ JT TEN	
09/14/20	COMMON	PREFERRED SERIES C ESCROWED COMMON SHARES FOR PREFERRED CONVERSION	100,000,000
09/14/20	COMMON	46 ROBERT LINZALONE	30,000,000
09/14/20	COMMON	135 JEFFERY J. KRUEGER	10,200,000
09/15/20	COMMON	135 JEFFERY J. KRUEGER	21,428,571
09/17/20	COMMON	681 Paul Soll	6,500,000
09/17/20	COMMON	417 JORDAN DESNER	650,000
09/17/20	COMMON	267 KEITH KLEPPE	1,100,000
09/17/20	COMMON	682 FRED GLANTZ	1,100,000
09/17/20	COMMON	683 GILBERT ROMOFF	2,100,000
09/17/20	COMMON	684 VICTOR BARDACK	2,100,000
09/17/20	COMMON	686 DAVID ROSE	1,100,000
09/17/20	COMMON	688 GODOY FAMILY TRUST	7,333,333
09/22/20	COMMON	690 James Lederer	2,500,000
09/25/20	COMMON	681 Paul Soll	3,500,000
09/25/20	COMMON	685 Jerry S Phillips	1,850,000

10/01/20	COMMON	663 Carran Schneider	10,000,000
10/06/20	COMMON	DOVECOTE CONSULTING (Anthony Pizzolo)	20,000,000
10/09/20	COMMON	673 Brad Novak	1,000,000
10/09/20	COMMON	498 Blackthorne Development (Mike Collins)	33,631,000
10/09/20	COMMON	672 Brian Ballo Family Living Trust	1,000,000
10/26/20	COMMON	551Trinity Financing Investments	11,679,484
10/26/20	COMMON	437 BOHDAN RUDAWSKI	15,165,154
10/26/20	COMMON	673 Brad Novak	1,250,000
10/26/20	COMMON	728 Richard Landry	2,500,000
10/26/20	COMMON	567 Steven Medina	7,225,000
10/29/20	COMMON	DREAMTECH INC. (Anthony Pizzolo)	20,000,000
11/16/20		633 SOAR HOLDINGS SYNDICATE,(Steve Medina)	2,700,000
11/16/20	COMMON	636 ROSEMARIE ROTONDO	3,000,000
11/17/20	COMMON	Preferred Series A Escrowed Common Shares for Preferred Conversion	100,000,000
11/20/20	COMMON	654 Lee H. Puglisi	4,000,000
11/20/20	COMMON	586 HESTIA INVESTMENTS INC(Edward Lee)	2,635,620
12/10/20	COMMON	10 RHONDA ADAMS	2,000,000
12/22/20	COMMON	618 EMANUEL KRAMER	5,965,017
12/22/20	COMMON	509 CARL LAW	5,250,000
12/22/20	COMMON	728 Richard Landry	5,000,000
12/22/20	COMMON	732 William Bryniarski	5,510,000
12/23/20	COMMON	547 THE VILLANO FAMILY LIMITEDPAR (Linda Villano)	100,000
12/29/20	COMMON	126 SAMUEL SCHLESINGER	2,700,000
12/29/20	COMMON	784 LEON BORSTEIN	1,500,000

B. Debt Securities, Including Promissory and Convertible Notes

Use the chart and additional space below to list and describe any issuance of promissory notes, convertible notes or convertible debentures in the past two completed fiscal years and any subsequent interim period.

Check this box if there are no outstanding promissory, convertible notes or debt arrangements: XX

Date of Note Issuance	Outstanding Balance(\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of Instrument to shares)	Name of Note holder	Reason for Issuance (e.g. Loan, Services, etc.)
--	--	--	--	--	--	--	--

Financial Statements

A The following financial statements were prepared in accordance

with: **XXU.S.GAAP**

B. The financial statements for this reporting period were prepared by Bruce Weitzberg)

Name: Bruce Weitzberg

Title: CEO

Relationship to Issuer: Bruce Weitzberg

CEO

Provide the financial statements described below for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any

subsequent interim periods.

- C. Balance sheet; ATTACHED
- D. Statement of income; ATTACHED
- E. Statement of cash flows; ATTACHED
- F. Financial notes; and
- G. Audit letter, if audited

You may either (i) attach/append the financial statements to this disclosure statement or (ii) file the financial statements through OTCIQ as a separate report using the appropriate report name for the applicable period end. ("Annual Report, a "Quarterly Report" or "Interim Report").

If you choose to publish the financial statements in a separate report as described above, you must state in the accompanying disclosure statement that such financial statements are incorporated by reference. You may reference the document(s) containing the required financial statements by indicating the document name, period end date, and the date that it was posted to OTCIQ in the field below.

The financial statements requested pursuant to this item must be prepared in accordance with US **GAAP** or IFRS by persons with sufficient financial skills.

- A. Describe any subsidiaries, parents, or affiliated companies, if applicable, and a description of their business contact information for the business, officers, directors, managers or control persons. Subsidiary information may be included by reference

PASHealth management Inc.is the wholly owned subsidiary of the Company that oversees and manages the medical facility-Same management

- B. Describe the issuers' principal products or services, and their
markets Healthcare management

4) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

None

5) Officers, Directors, and Control Persons

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Using the tabular format below, please provide information regarding any person or entity owning 5% of more of the issuer, as well as any officer, and any director of the company, regardless of the number of shares they own. If any listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information of an individual representing the corporation or entity in the note

section.

Name of Officer/Director and Control Person	Affiliation with Company (e.g. Officer/Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding
Bruce Weitzberg	CEO	14 fox hollow rd.	23,000,000	common	1.9%
		Woodbury, NY			
Bruce Weitzberg	CEO	14 fox hollow rd.	5,000,000	Preferred ¹	50%
		Woodbury, NY			
Robert Linzalone	VP	15 Wheatfield rd	47,672,159	common	4.1%
		Commack, NY			
Robert Linzalone	VP	15 Wheatfield	5,000,000	preferred ¹	50%
		Commack NY			
Jeffery Krueger	Own more than 5%	607 Elm St West Bend, WI	61,839,436	common	5.3%

¹ Each Preferred A share entitles the holder to vote the equivalent of 100 shares of common stock. Accordingly, the holder of 5,000,000 Preferred A shares entitles the holder to vote the equivalent of 500,000,000 shares of common stock, in addition to common stock already held by such holder. Therefore, the holder of 5,000,000 shares of Preferred A has at least a 23% voting interest, in addition to voting rights of common shares held by such holder. The holder of Preferred A may, at any time, convert its Preferred A shares to common shares at a ratio of 100 common shares for each Preferred A share. Accordingly, each holder of 5,000,000 Preferred A shares, upon conversion of all 5,000,000 Preferred A shares would hold at least 500,000,000 common shares (23%) in addition to common shares already held.

6) Legal/Disciplinary History

A Please identify whether any of the persons listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses); None
2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities; None
3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or None

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.
None

no

B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities. None

7) Third Party Providers

Please provide the name, address, telephone number and email address of each of the following outside providers:

Securities Counsel

Name: Firm: Legal Counsel
Law Offices of Kramer, LLC
eck@lawkram.com
260 Madison Avenue, 16th Floor
New York, NY 10016

Accountant or Auditor Name:

Firm:

Address 1: Address 2: Phone: Email:

Michael Studer Studer Associates
111 West Sunrise Hwy Freeport. NY 11520 516-
378-1000
mts@studerpa.com

Other Service Providers

Provide the name of any other service provider(s), including, counsel, advisor(s) or consultant(s) that assisted, advised, prepared or provided information with respect to this disclosure statement, or provided assistance or services to the issuer during the reporting period.

8) Issuer Certification


Principal Executive Officer.

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities).

The certifications shall follow the format

below: I, Bruce Weitzberg certify that:

1. I have reviewed this Quarterly report dated January 31, 2021 of PASO;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

— [CEO's Signature] 

(Digital Signatures should appear as "/s/ [OFFICER NAME]")
January 31, 2021

Principal Financial Officer.

I, Bruce Weitzberg certify that

1. I have reviewed this Quarterly report dated January 31, 2021 of PASO;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of and for the periods presented in this disclosure statement.

January 31, 2021 [Date]
[CFO's Signature] 

(Digital Signatures should appear as "/s/ [OFFICER NAME]")

PATIENT ACCESS SOLUTIONS

Profit and Loss

November 2020 - January 2021

	TOTAL	
	NOV 2020 - JAN 2021	NOV 2019 - JAN 2020 (PY)
Income		
30500 Sales	43,692.00	177,958.00
Total Income	\$43,692.00	\$177,958.00
GROSS PROFIT	\$43,692.00	\$177,958.00
Expenses		
60000 Advertising		1,312.40
60002 Marketing	150.00	150.00
60100 petty cash	200.00	1,211.00
60400 Bank Charges	200.00	200.00
61700 Computer/Network Fees	3,350.00	1,420.00
62500 Dues & Subscriptions	340.00	340.00
63300 Insurance	606.23	606.23
63350 Insurance - Disability	1,214.36	
64400 Other General and Admin Expenses	2,500.00	37,869.23
64600 medical supplies		13,296.00
64900 Office Expenses	6,123.00	29,955.10
64901 Supplies & Materials	8,123.00	
66001 Payroll Wages-PAS	6,221.00	14,024.00
66700 Legal & Professional Fees	5,000.00	6,499.21
67100 Rent or Lease	11,225.00	85,952.00
67101 Utilities	2,788.00	5,784.00
69822 Consulting fees(Stock-based)	60,000.00	
Total Expenses	\$108,040.59	\$198,619.17
NET OPERATING INCOME	\$ -64,348.59	\$ -20,661.17
NET INCOME	\$ -64,348.59	\$ -20,661.17

PATIENT ACCESS SOLUTIONS

Balance Sheet

As of January 31, 2021

ASSETS

Current Assets

	AS OF JAN 31, 2021	AS OF JAN 31, 2020 (PY)
Bank Accounts		
7690 Checking	9,927.45	1,885.68
7691 Checking Operating	0.00	3,941.28
7693 Account Closed	0.00	-75.00
7694 Bank Transfer	0.00	8,787.00
Total Bank Accounts	\$9,927.45	\$14,538.96
Accounts Receivable		
10001 Accounts Receivable (A/R)	124,828.77	2,023,786.77
Total Accounts Receivable	\$124,828.77	\$2,023,786.77
Other Current Assets		
11400 Prepaid Expenses	40.00	40.00
12001 Senior Secured Credit cash in escrow pending settlement of NYS income tax withholding liability	12,032.00	12,032.00
12002 Prepaid rent	23,246.67	23,246.67
12003 Supplies Inventory	7,213.89	7,213.89
12223 Allowance for Bad Debts	2,100,000.00	
13101 Uncategorized Asset	2,984.01	2,984.01
Total Other Current Assets	\$2,145,516.57	\$45,516.57
Total Current Assets	\$2,280,272.79	\$2,083,842.30
Fixed Assets		
13000 Furniture & Fixtures	106,337.36	106,337.36
13001 Machinery & Equipment	142,893.19	142,893.19
13002 Computers etal	55,030.46	55,030.46
13005 Leasehold Improvements	383,792.36	383,792.36
13100 Accumulated Depreciation		
131000 Accumulated Depletion- furniture and fixture	-10,426.58	-10,426.58
131001 Accumulated depreciation - machinery and equipment	-11,049.78	-11,049.78
131002 Accumulated Depletion- computers	-6,377.72	-6,377.72
131005 Accumulated Depletion-leasehold improvement	-17,682.84	-17,682.84
Total 13100 Accumulated Depreciation	-45,536.92	-45,536.92
Total Fixed Assets	\$642,516.45	\$642,516.45
Other Assets		
11200 Loan to Company	-20,000.00	-20,000.00
14001 Security deposit	46,493.34	46,493.34
Total Other Assets	\$26,493.34	\$26,493.34
TOTAL ASSETS	\$2,949,282.58	\$2,752,852.09

LIABILITIES AND EQUITY

Liabilities

Current Liabilities

	TOTAL	
	AS OF JAN 31, 2021	AS OF JAN 31, 2020 (PY)
Accounts Payable		
20000 Accounts Payable (A/P)	-223,942.27	128,180.37
Total Accounts Payable	\$ -223,942.27	\$128,180.37
Other Current Liabilities		
20001 Due to Stella Realty	0.00	0.00
20002 Social security - employer liabilities	-2,307.14	-2,307.14
20003 Social security withhold	-1,107.14	-1,107.14
20004 Federal income tax withhold	-67,666.86	-67,666.86
20005 NYS income tax withhold	-1,029.60	-1,029.60
21001 Loan payable CIIT	-195,000.00	-195,000.00
22001 Loan payable - Senior Secured Credit (due 9/15/17)	568,125.00	568,125.00
22002 Debt discounts-loan payable-Senior Secured Credit	-33,118.66	-33,118.66
22003 Interest payable	30,500.00	30,500.00
24110 NYS income tax withholding liability	0.00	0.00
24150 Federal Taxes	158,681.00	158,681.00
25001 Deferred Additional Revenue Share Expense	-500,000.00	-500,000.00
25002 Additional Revenue Share Payable	500,000.00	500,000.00
27001 Series B Preferred Stock (Redeemable and Convertible)	200,000.10	200,000.10
27332 Payroll Liabilities	-11,109.00	-11,109.00
27333 Connectcare	3,600.00	3,600.00
45000 Federal Taxes (941/944)	90,431.08	-59,568.92
45001 Federal Unemployment (940)	799.61	799.61
45002 NY MCTMT Employer Tax	0.00	0.00
45003 NYS Employment Taxes	-12,592.34	-12,592.34
45004 NYS Income Tax	25.90	25.90
Total 27332 Payroll Liabilities	71,155.25	-78,844.75
37400 Accrued rent expense	0.00	0.00
37401 Convertible Notes	0.00	361,000.00
Contra convertible notes payable	25,000.00	-336,000.00
Due to bruce	0.00	500.00
Total Other Current Liabilities	\$753,231.95	\$603,731.95
Total Current Liabilities	\$529,289.68	\$731,912.32
Total Liabilities	\$529,289.68	\$731,912.32
Equity		
11301 Common Stock PPM	6,000.00	156,000.00
28001 Common Stock, \$.001 pa	595,816.18	94,695.18
28002 Additional paid-in capital	16,431,776.20	16,432,684.48
28501 Series A Convertible Preferred Stock, \$.001 pa	9,999.90	9,999.90
32000 Retained Earnings	-15,154,551.50	-15,247,079.33
Opening Balance Equity	595,300.71	595,300.71
Net Income	-64,348.59	-20,661.17
Total Equity	\$2,419,992.90	\$2,020,939.77
TOTAL LIABILITIES AND EQUITY	\$2,949,282.58	\$2,752,852.09

PATIENT ACCESS SOLUTIONS

Statement of Cash Flows

November 2020 - January 2021

	Totals
OPERATING ACTIVITIES	
Net Income	-64,348.59
Adjustments to reconcile Net Income to Net Cash provided by operations:	
10001 Accounts Receivable (A/R)	-43,692.00
20000 Accounts Payable (A/P)	-477,758.64
22001 Loan payable - Senior Secured Credit (due 9/15/17)	0.00
24150 Federal Taxes	
37401 Convertible Notes	-361,000.00
Contra convertible notes payable	361,000.00
Due to bruce	-500.00
Total Adjustments to reconcile Net Income to Net Cash provided by operations:	-521,950.64
Net cash provided by operating activities	\$ -586,299.23
FINANCING ACTIVITIES	
28001 Common Stock, \$.001 pa	501,121.00
28002 Additional paid-in capital	-908.28
Net cash provided by financing activities	\$500,212.72
NET CASH INCREASE FOR PERIOD	\$ -86,086.51
Cash at beginning of period	96,013.96
CASH AT END OF PERIOD	\$9,927.45

Patient Access Solutions, Inc.
Statement of Shareholders Equity
For period Ending January 31, 2021

	Preferred Stock @ \$1 par	Common Stock @.001 par	Additional Paid In Capital	Retained Earnings	Total
Balance, October 31,2020	10,000,000	1,157,825,270	144,500	-16,689,043.	-6,276,338
Issuance of additional common stock	0	140,360,637-			121,546
Purchase of Treasury Stock	0				
Net Income	0				190,027.64
Dividends on Preferred Stock	0	0	0	0	0
Dividends on Common Stock	0	0	0	0	0
Balance, January 31`, 2021	10,000,000	1,298,185,907	156,000	-16,716,428	-6,170,676

January 31, 2021 Quarterly Report-

Financial statement information is considered current until the due date for the subsequent report (as set forth in the qualifications section above). To remain qualified for Current Information, a company must post its Annual Report within 90 days from its fiscal year-end date and Quarterly Reports within 45 days of each fiscal quarter-end date.

9) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations. In answering this item, please include the following:

C. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

Patient Access Solutions Inc. has developed and markets the PASHealth Web Portal System. The PASHealth Web Portal System offers electronic medical eligibility, electronic referrals, and service authorizations, electronic claims processing, drug formularies, electronic prescriptions, electronic medical records and patient data, automating the labor intensive and expensive manual process currently used by many facilities and healthcare providers. D-PAS utilizes digital pen & paper, to capture handwritten information for Home Healthcare workers, transfer it into a digital form into the PAS web portal and utilize the data to initiate workflows in a secure environment. A patients' medical history and patient records are used to initiate necessary workflows within the web portal, securely and much more efficiently, empowering the healthcare business process. In addition, the Web Portal System offers a complete suite of self-pay receivable management solutions for the healthcare facilities.

In January 2017 the Company opened up an Integrative Medical Facility in Plainview, New York.

For the Quarter ended January 31, 2021 Recent Developments: As a result of the COVID-19 pandemic, we expected our revenue for the year ended October 31, 2020 to be reduced by 90% compared to our revenue for the year ended October 31, 2019. The rapid spread of COVID-19, as well as the measures governments and private organizations have implemented in order to stem the spread of this pandemic, have had, and are continuing to have, a material adverse effect and consequently upon our business.

- In New York, which is our primary market, the government has encouraged social distancing efforts and limits on gathering size, placed significant restrictions on which kind of medical services are considered “essential”;
- State or local governments have issued health-related curfews or “shelter in place” orders which dissuade any provider visits that aren't considered critical/emergency;
- Employers in both the public and private sectors have issued instructions to employees to work from home having a ripple effect on consumers having the ability to visit a physician for elective procedures;
- Consumers discouraged from interacting with society where COVID-19 is particularly virulent;

These effects related to the COVID-19 pandemic are negatively impacting our business in general, which in turn are materially adversely affecting our revenues and results of operations. Although certain of the restrictions above have begun, and may continue, to ease, the ongoing pandemic, including concentrated outbreaks of COVID-19, may result in their reinstitution. Moreover, additional currently unknown restrictions (including possibly in the near term), lengthening the negative effects of the COVID-19 pandemic on our business.

Our operations could be negatively affected further if our employees are sickened as a result of exposure to COVID-19.

In response to the crisis, we are taking certain steps to mitigate the effects on our business, which themselves may have negative consequences with respect to our business and operations. For example, we have significantly reduced our operating capacity. Despite these efforts, we have experienced significant appointment cancellations. Cancellations and related refunds have negatively affected our revenues and liquidity, and we expect such negative effects to continue. Other cost-saving measures that we are implementing or may consider, such as deferral of nonessential maintenance, capital expenditure reductions, hiring freezes. The pandemic is also having a material adverse effect on third parties whose services we utilize. Depending on the duration of the pandemic, such negative developments may occur over the entirety of the event. At this time, we are also not able to predict whether the COVID-19 pandemic will result in permanent changes to our customers' behavior, with such changes including but not limited to a permanent reduction in office visits and treatment. All of the foregoing have had a material adverse effect on our business, results of operations and financial condition.

Patient Access Solutions Inc. (“PASO”) was incorporated in the state of Nevada on March 17, 2006. Its wholly owned subsidiary PAS Health Management Companies NY, Inc. (“PASO Health”), incorporated in the State of New York on October 1, 2016, provides administrative, management, and facility services to health care providers at locations in Plainview New York and Center Moriches New York). PASO also rents equipment to other health care providers.

PASO and PASHealth Management Companies NY are collectively referred to as the “Company”.

The Unaudited Financial Statements as of January 31, 2021, have been prepared in accordance with accounting principles generally accepted in the United States. In the opinion of management. the unaudited financial statements reflect all adjustments, which include only normal recurring adjustments, necessary to present fairly the financial data and other information disclosed in these notes. The results for these periods are not necessarily indicative of the results to be expected for future periods.

2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (a) Basis of Presentation and Going Concern

The financial statements are prepared on a "going concern" basis, which contemplates the realization of assets and liabilities in the normal course of business; however, there is substantial doubt as to the Company's ability to continue as a going concern.

The Company plans to improve its financial condition by obtaining additional financing and by generating positive cash flow from its future business operations. However, there is no assurance that the Company will be successful in accomplishing its objectives. The financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

(b) Principles of Consolidation

The Unaudited Consolidated financial statements include the accounts of PASO and its wholly owned subsidiary PASO Health (collectively, the "Company"). All inter-company balances and transactions have been eliminated in consolidation.

(c) Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the dates of the financial statements and the reported amounts of revenues and expenses during the reporting periods. Actual results could differ from those estimates.

(d) Cash and Cash Equivalents

The Company considers all liquid investments purchased with original maturities of ninety days or less to be cash equivalents.

(e) Fees and Loans Receivable from Health Care Providers

Fees receivable from health care providers are recorded at net realizable value. The Company periodically assesses the adequacy of valuation allowances for uncollectable receivables by evaluating the collectability of outstanding receivables and general factors such as historical collection experience, length of time individual receivables are past due, and the economic and competitive environment.

(f) Property, Plant and Equipment

Property, plant and equipment is stated at cost less accumulated depreciation and amortization. Depreciation of furniture, fixtures, and equipment is provided using the straight-line method over the estimated useful lives of the respective assets (ranging from five to seven years). Amortization of leasehold improvements is provided over the shorter of the remaining lease term or the assets' useful lives.

(g) Revenue Recognition

Revenue from fees from health care providers and equipment rentals are recognized when all the following criteria are met: when persuasive evidence of an arrangement exists